AbbVie Inc. $ABBV Stock: Total Wealth Planning & Management Inc. Trims Position

Key Points

• Total Wealth Planning & Management Inc. cut its AbbVie stake by 83.5% in the third quarter, leaving the fund with 1,815 shares valued at approximately $475,000. Institutional investors collectively own 70.23% of AbbVie.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $279.86, despite some rating adjustments.
• AbbVie reported quarterly revenue of $16.99 billion and adjusted earnings of $3.65 per share, both ahead of expectations. The company also declared a quarterly dividend of $1.73 per share, representing a 2.4% yield.

Total Wealth Planning & Management Inc. lessened its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 83.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,815 shares of the company's stock after selling 9,197 shares during the quarter. Total Wealth Planning & Management Inc.'s holdings in AbbVie were worth $475,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Burk Holdings LLC purchased a new position in shares of AbbVie in the 2nd quarter valued at $30,000. Merkkuri Wealth Advisors LLC purchased a new stake in AbbVie during the 1st quarter worth $34,000. Marquette Asset Management LLC increased its holdings in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. IMG Wealth Management Inc. increased its holdings in AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after purchasing an additional 153 shares in the last quarter. Finally, Principia Wealth Advisory LLC boosted its position in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock worth $40,000 after buying an additional 44 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on ABBV shares. Argus boosted their price target on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Piper Sandler increased their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. Guggenheim reiterated a "buy" rating and set a $288.00 price objective on shares of AbbVie in a research note on Friday, October 9th. Finally, BMO Capital Markets boosted their target price on shares of AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $279.86.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $285.66 on Monday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40. The firm has a market cap of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24. The stock's 50-day simple moving average is $266.33 and its 200-day simple moving average is $242.01.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The company's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 13.93 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio is 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company's stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.